



## Differences in definitive endoderm induction approaches using growth factors and small molecules

Journal:	<i>Journal of Cellular Physiology</i>
Manuscript ID	Draft
Wiley - Manuscript type:	Original Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Bogacheva , Mariia; University of Helsinki, Faculty of Pharmacy            Khan, Sofia; National Institute of Advanced Industrial Science and Technology            Kanninen, Liisa; University of Helsinki, Faculty of Pharmacy            Yliperttula, Marjo ; University of Helsinki, Faculty of Pharmacy            Leung, Alan; Yale University, Yale Stem Cell Center and Department of Genetics, Yale School of Medicine            Lou, Yan-Ru; University of Helsinki, Faculty of Pharmacy</p>
Key Words:	Human pluripotent stem cell, Definitive endoderm, Cell differentiation

SCHOLARONE™  
Manuscripts

1  
2  
3 **Differences in definitive endoderm induction approaches using growth factors and small**  
4 **molecules**  
5  
6

7 Mariia S. Bogacheva <sup>1</sup>, Sofia Khan <sup>2</sup>, Liisa K. Kanninen <sup>1</sup>, Marjo Yliperttula <sup>1</sup>, Alan W. Leung <sup>3</sup>,

8  
9 Yan-Ru Lou <sup>1,\*</sup>  
10

11 <sup>1</sup> Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy,  
12 University of Helsinki, Helsinki, Finland  
13

14 <sup>2</sup> Computational Bio Big-Data Open Innovation Laboratory (CBBD-OIL), National Institute of  
15 Advanced Industrial Science and Technology (AIST), Tokyo, Japan  
16

17 <sup>3</sup> Yale Stem Cell Center and Department of Genetics, Yale School of Medicine, Yale University,  
18 New Haven, Connecticut, United States  
19

20 \* Corresponding author: Yan-Ru Lou  
21

22 Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56  
23 (Viikinkaari 5 E), FI-00014 Helsinki, Finland  
24

25 E-mail address: [yan-ru.lou@helsinki.fi](mailto:yan-ru.lou@helsinki.fi); Tel: +358 2941 59125  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

Definitive endoderm (DE) is the first stage of human pluripotent stem cell (hPSC) differentiation into hepatocyte-like cells. Developing human liver cell models for pharmaceutical applications is highly demanding. Due to the vast number of existing protocols to generate DE cells from hPSCs, we aimed to compare the specificity and efficiency of selected published differentiation conditions. We differentiated two hPSC lines (induced PSC and embryonic stem cell) to DE cells on Matrigel matrix using growth factors (Activin A and Wnt-3a) and small molecules (sodium butyrate and IDE 1) in different combinations. By studying dynamic changes during six days in cell morphology and the expression of markers for pluripotency, DE, and other germ layer lineages, we found that Activin A is essential for DE differentiation, while Wnt-3a and sodium butyrate are dispensable. Although sodium butyrate exerted rapid DE differentiation kinetics, it caused massive cell death and could not generate sufficient cells for further differentiation and applications. We further discover that IDE 1 could not induce DE as reported previously. Hereby, we compared different conditions for DE induction and found an effective six day-protocol to obtain DE cells for the further differentiation and applications.

**KEYWORDS**

Human pluripotent stem cell; Definitive endoderm; Cell differentiation

## 1 INTRODUCTION

Differentiation of human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), into hepatocyte-like cells *in vitro* is a promising approach to creating a human cell model for drug toxicity screening. Considering the fact that obtaining mature hepatocytes remains challenging (Schwartz et al., 2014), there is a necessity for detailed study of each step of hPSC differentiation. The purity, maturity, and functionality of hepatocyte-like cells highly depend on the efficacy of every step of the differentiation process. The first defined cell stage of differentiation is the formation of definitive endoderm (DE) characterized by the expression of transcription factors such as SRY-box 17 (SOX17), mix paired-like homeobox (MIXL1), hepatocyte nuclear factor 3 $\beta$  (HNF3B, also known as FOXA2) and receptors such as chemokine receptor type 4 (CXCR4). The DE contributes cell precursors to many organs including the liver, pancreas, thyroid, thymus, digestive tracts, to epithelial lining of the respiratory tracts and lungs. The DE stage defines further cell fate, depending, in part, on extracellular conditions. Controlled formation of DE *in vitro* and further hepatic lineage differentiation holds an enormous potential for therapeutic and pharmaceutical applications.

In vertebrates the Nodal (transforming growth factor  $\beta$  (TGF $\beta$ )-related ligand) signaling, mediated by Mixer homeoproteins, is required for the DE development in a dose-dependent manner (Shen, 2007). In this study, we examined the influence of different growth factors and small molecules, including Activin A (AA), Wnt-3a, Sodium Butyrate salt (NaB), IDE 1 and their combinations during the induction of DE differentiation. AA, similar to Nodal, is a member of the TGF $\beta$  superfamily which participates in regulation of several biological processes, including cell differentiation and proliferation. During normal embryonic development, AA plays an important role in endoderm/mesoderm formation and patterning in a concentration dependent manner and has been used at high concentration in generation of DE cells from hPSCs (D'Amour et al., 2005). Wnt-3a is a cysteine-rich glycoprotein and a ligand of Wnt-signaling, which participates in primitive

1  
2  
3 streak cell type formation from ESC (Gadue et al., 2006; Lindsley et al., 2006) and in human  
4  
5 hepatic endoderm development (Hay et al., 2008a). NaB is a histone deacetylase inhibitor which  
6  
7 has an anti-proliferative and differentiation-inducing activity in various normal cells (Boffa et al.,  
8  
9 1978; Kruh, 1982) and has been used in differentiation of ESCs to DE cells (Hay et al., 2008b;  
10  
11 Jiang et al., 2007) and early pancreatic progenitors (Goicoa et al., 2006). IDE 1 is a synthetic small  
12  
13 cell-permeable molecule that can activate TGF $\beta$  signaling. It was shown to promote direct  
14  
15 differentiation of ESCs into the endodermal lineage and was more potent than AA or Nodal in  
16  
17 promoting DE induction (Borowiak et al., 2009).  
18  
19

20  
21 In the present study, we identified an efficient and robust method for DE cell differentiation from  
22  
23 hESCs and hiPSCs among four most frequently used protocols.  
24  
25

## 26 27 **2 RESULTS**

### 28 29 **2.1 Cell morphological changes during differentiation**

30  
31 We earlier used the two hPSC lines WA07 and iPS(IMR90)-4 in hepatic differentiation studies by  
32  
33 using M1 media for six days in generation of DE (Kanninen et al., 2016a; Kanninen et al., 2016b).  
34  
35 We had also tested M5, but due to massive cell death we could not obtain enough DE cells for  
36  
37 hepatic specification. To find a more effective DE induction method preferably shorter than six  
38  
39 days and based on small molecules, we performed DE induction in both cell lines with six different  
40  
41 compositions of differentiation media (Table 1). We purchased NaB from three manufactures to  
42  
43 find a less toxic one if cell death was caused by chemical impurity. The concentrations of growth  
44  
45 factors and small molecules used in the present study were chosen from the literature (Borowiak et  
46  
47 al., 2009; D'Amour et al., 2005; Hay et al., 2008b; Tahamtani et al., 2013; Toivonen et al., 2013).  
48  
49 Both WA07 and iPS(IMR90)-4 cells displayed typical stem cell morphology during culturing  
50  
51 before differentiation procedure (Figures 1 and 2). We monitored cell morphology during  
52  
53 differentiation experiments and observed gradual change of cell shape and reorganization of stem  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 cell colonies to single cells. The speed of morphological changes varied in both cell lines,  
4  
5 depending on the differentiation media. Figures 1 and 2 show differences at three time points – days  
6  
7 1, 4, and 6. Treatment of WA07 cells with M1 and M2 led to gradual morphological changes  
8  
9 starting after day 1 checkpoint: cells in colonies became loose and some cells acquired  
10  
11 mesenchymal-like morphology (Figure 1). By day 6 the cells not only acquired DE morphology,  
12  
13 but also grew and proliferated into a monolayer. We noticed that the fastest differentiation started  
14  
15 upon the treatment with NaB-containing media; however, those cells had very low survival rate.  
16  
17 After 24 hours of NaB treatment, cell number was decreased at least in half, and on day 6 of  
18  
19 differentiation an extremely low number of cells survived. Additionally we tested NaB at lower  
20  
21 concentrations: a) 0.8 mM for priming stage (first 24 hours), followed with 0.4 mM for induction  
22  
23 (days 1-5); b) 0.5 mM for both priming and induction; c) 0.5 mM at priming stage followed with  
24  
25 0.1 mM for induction. We did not observe an improved cell survival with lower concentrations of  
26  
27 NaB (data not shown). Among three studied NaB-containing media, NaB from Millipore showed  
28  
29 the highest toxicity. After day 4 checkpoint there was the smallest number of attached cells in M3-  
30  
31 treated wells that were not enough for the analysis of gene expression profile. Since WA07 cell line  
32  
33 showed extremely low survival with this condition, we excluded M3 in the subsequent experiments.  
34  
35 M6 media based on IDE 1 most likely did not affect cell morphology because no cells with DE  
36  
37 morphology were observed during the differentiation and cells overgrew and their morphology  
38  
39 became unclear by the end of the differentiation experiments. To know if IDE 1 at higher  
40  
41 concentrations can induce DE differentiation, we tested IDE 1 at 250, 500, and 1000 nM but did not  
42  
43 observe any morphological changes. We treated iPS(IMR90)-4 cells with five different media: M1,  
44  
45 M2, M4, M5, and M6. Cells exhibited similar morphological changes as seen in WA07 culture with  
46  
47 the only distinction that more cells survived after treatments with NaB-containing media (Figure 2).

## 54 **2.2 Characterization of gene expression profiles in stem cells and their derivatives**

1  
2  
3 To understand how treatments with different media conditions affect the DE differentiation, we  
4 studied gene expression profiles of the hPSCs and their derivatives during differentiation process at  
5 three time points (same as we observed morphology transformation) by qPCR. We compared gene  
6 expression levels of specific markers for pluripotency, DE, mesoderm, and ectoderm with those in  
7 undifferentiated stem cells to show the kinetics of up and downregulations. In WA07-derived DE  
8 cells, the mRNA expression levels of the pluripotency marker *OCT4* (encoding octamer-binding  
9 protein 4) significantly decreased by day 6 of differentiation in cells treated with all conditions  
10 comparing with undifferentiated cells (Figure 3a). The cells in M4 did not survive for 6 days. The  
11 loss of *OCT4* indicates the differentiation induced by soluble factors. The expression level of the  
12 second pluripotency marker we measured, *NANOG* (encoding Nanog homeobox transcription  
13 factor), did not significantly decrease in most cases except in the cells in M6 beginning from day 4  
14 (Figure 3b). Comparing with undifferentiated cells, the mRNA expression level of DE marker  
15 *CER1* (Cerberus 1) increased significantly in most cases from day 4 except the cells in M6 (Figure  
16 3c). M1 and M5 caused significant increase in *CER1* mRNA expression from day 4 to day 6.  
17 Comparing with undifferentiated cells, the expression level of *SOX17* increased in the cells in M2  
18 from day 1 and in the others from day 4, but it did not change significantly in M6 (Figure 3d).  
19 Comparing with undifferentiated cells, *CXCR4* increased in the cells in M1, M2, M4, and M5 from  
20 day 4 but not in M6 (Figure 3e). M1 and M5 treatments induced further increase in *CXCR4*  
21 expression from day 4 to day 6, whereas M2 treatment caused slight decrease in *CXCR4* as well as  
22 in *SOX17*. Comparing with undifferentiated cells, *HNF3B* gene expression was significantly  
23 induced in the cells in M2 from day 1 and cells in M4 and M5 from day 4 of differentiation (Figure  
24 3f). M1 also increased *HNF3B* gene expression to the similar level by day 6 as M2, but the increase  
25 was not statistically significant. M5 treatment significantly upregulated *HNF3B* expression from  
26 day 4 to day 6. *HNF4A* expression increased mostly on day 4 and day 6 in comparison with day 0,  
27 except for the cells in M6 which did not cause significant change (Figure 3g). M1 and M5  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treatments further upregulated *HNF4A* expression from day 4 to day 6. Expression of hepatocyte  
4 nuclear factor 6 (*HNF6*) was unaltered in most conditions except in M6 on day 4 (Figure 3h). The  
5 level of *BRACHYURY* mRNA expression peaked on day 1 of differentiation in all the conditions  
6 except M6, afterwards it decreased to the level similar to that in stem cells (Figure 3i). The  
7 expression of ectoderm marker SRY-box 1 (*SOX1*) increased in the cells in M4 and M5 from day 4  
8 (Figure 1j).

9  
10  
11  
12  
13  
14  
15  
16 In iPS(IMR90)-4 cells *OCT4* mRNA expression was slightly upregulated in M1, M4, and M5 on  
17 day 1 and then downregulated in all the conditions from day 4 in comparison with day 0 (Figure  
18 4a). *NANOG* gene expression was downregulated in M2 and M6 but was upregulated in other  
19 conditions (Figure 4b). *CER1* mRNA expression was upregulated during the differentiation in all  
20 the conditions except M6 (Figure 4c). Gene expression level of *SOX17* became significantly higher  
21 from day 1 of differentiation in M2 and from day 4 in M1, M4, and M5 (Figure 4d). *CXCR4* (Figure  
22 4e), *HNF3B* (Figure 4f), and *HNF4A* (Figure 4g) mRNA expression significantly increased from  
23 day 4 in M1, M2, M4, and M5. *HNF6* mRNA expression level slightly increased from day 1 in the  
24 cells in M4 and M5 and from day 4 in M1, but it decreased in M6 (Figure 4h). *BRACHYURY*  
25 mRNA expression was first upregulated on day 1 in M1, M2, M4, and M5 and then decreased by  
26 day 4 (Figure 4i). *SOX1* gene expression slightly increased in M5 at all the time points, in M6 on  
27 day 1, and in M1 and M4 on day 4 (Figure 4j). In addition, we found significant increase in *CER1*,  
28 *CXCR4*, *HNF3B*, and *HNF4A* gene expression from day 4 to day 6 in conditions M1, M2, M4, and  
29 M5. However, *SOX17* expression was slightly decreased from day 4 to day 6 in M1 and M5.

### 2.3 Analysis of hierarchical cluster plots

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
By using hierarchical cluster analysis, we grouped medium conditions in clusters according to their  
influence on gene expression (Figure 5). Hierarchical analyses for both cell lines showed  
similarities between conditions M1 and M2 and between conditions M4 and M5. Condition M6 had  
dissimilarities with both groups.



## 2.4 Characterization of cell markers at the protein level

After gene expression profile analyses, we concluded that conditions M1 and M2 led to significant increase of DE gene markers by day 6 and provided satisfactory cell survivals. We analyzed protein expression of pluripotency and DE markers by immunofluorescence staining and further confocal microscope and fluorescent microscope imaging (Figures 6 and 7). The majority of DE cells from both cell lines lost OCT4 after 6-day treatment with M1 and M2 media conditions (Figures 6a and 7a). Fluorescent signals for NANOG in both cell lines after differentiation in M1 and M2 decreased, but did not disappear completely (Figures 6b and 7b) that is in agreement with qPCR results (Figures 3b and 4b). Similar to the upregulation of *SOX17* mRNA expression (Figures 3d and 4d), *SOX17* protein expression was also increased in the cells in both conditions M1 and M2 as indicated by bright immunofluorescence (Figure 6 and 7). On the other hand, *HNF3B*, which significantly increased at the mRNA level in both cell lines in M2 and in iPS(IMR90)-4-derived cells in M1 (Figures 3f and 4f), showed weak positive immunofluorescence (Figures 6 and 7). The expression of *HNF4A* in the iPS(IMR90)-4-derived cells after treatment with M1 was weaker than that in the cells in M2. In WA07-derived cells the brightness of signals was similar for both treatment conditions. Alpha fetoprotein (AFP) is a specific hepatic marker and is absent from DE. In our experiments all the differentiated cells were AFP-negative.

## 3 DISCUSSION

This study presents efficient DE cell formation from hPSCs *in vitro* using soluble factors in serum-free condition. Main properties of hiPSCs and hESCs are indefinite proliferation *in vitro* and the ability to differentiate into a large number of cell types *in vitro* and *in vivo*. These features are maintained by the expression of pluripotent transcription factors, including OCT4 (Nichols et al., 1998) and NANOG (Chambers et al., 2003; Mitsui et al., 2003). Downregulation of OCT4 was accompanied by the loss of pluripotency properties and gain of specialization during the

1  
2  
3 differentiation experiments with current protocols. In most cases we did not observe changes in  
4  
5 *NANOG* mRNA expression, but we observed decrease in its protein expression. Considering the  
6  
7 fact of *NANOG* expression activation by TGF $\beta$ /Activin signaling (Xu et al., 2008), its stable mRNA  
8  
9 expression during experiments does not indicate differentiation failure. An earlier study reported  
10  
11 that each pluripotency marker had specific kinetics of downregulation during differentiation into  
12  
13 three germ layers, OCT4 being lost by day 9 of differentiation whereas *NANOG* was still detectable  
14  
15 on day 9 (Ramirez et al., 2011).  
16

17  
18 During gastrulation, DE and mesoderm emerge from a common precursor known as  
19  
20 mesendoderm in the primitive streak via an epithelial-to-mesenchymal transition. In our studies, we  
21  
22 observed morphological change of hPSCs towards mesenchymal-like cells. Bipotential  
23  
24 BRACHYURY positive cells can give rise to DE and mesoderm cells (Kubo et al., 2004).  
25  
26 BRACHYURY is also expressed in mesoderm and controls the organization of mesoderm  
27  
28 (Wilkinson et al., 1990). We confirmed the transient expression of BRACHYURY on day 1  
29  
30 indicating the emergence of mesendoderm population, which is in concordance with previous  
31  
32 research by Hay and co-authors, showing that in the first priming stage of differentiation, cells  
33  
34 passed through mesendoderm to DE (Hay et al., 2008b). By day 6 of differentiation, the expression  
35  
36 of BRACHYURY in most cases returned to a similar level to that in stem cells.  
37  
38  
39

40  
41 For identification of DE formation efficacy, we checked gene expression dynamics of four  
42  
43 markers: *CER1*, *SOX17*, *CXCR4* and *HNF3B*. *CER1* is a DE marker, whose role is to inhibit  
44  
45 NODAL signaling (Katoh and Katoh, 2006). *SOX17* is an important protein for the development of  
46  
47 DE (Kanai-Azuma et al., 2002) and for further foregut differentiation (Spence et al., 2009). *CXCR4*  
48  
49 is expressed in large variety of cell types including DE (McGrath et al., 1999). *HNF3B* (*FOXA2*) is  
50  
51 a transcription factor expressed by the primitive streak and continuously expressed by DE  
52  
53 progenitors (Ang et al., 1993). It is involved in the development of multiple endoderm-derived  
54  
55 organ systems such as the liver, pancreas, and lungs. In this study, we found that NaB-containing  
56  
57  
58  
59  
60

1  
2  
3 conditions more effectively upregulated *SOX17*, *CXCR4*, and *HNF3B* mRNA expression than the  
4  
5 other conditions. The difference is clearly observed in WA07-derived cells. Successful DE  
6  
7 formation in conditions M1, M2, M4, and M5 was evidenced by the simultaneous upregulation of  
8  
9 several DE markers. Six-day DE induction in conditions M1, M2, M4, and M5 is more efficient  
10  
11 than four day-induction in terms of gene expression upregulation of DE markers. Our results show  
12  
13 that IDE 1 did not lead to DE induction, which is in agreement with an earlier report showing no  
14  
15 increase in the expression of *SOX17*, *FOXA2*, and *CXCR4* (Tahamtani et al., 2013). Given the fact  
16  
17 that pluripotency markers were downregulated, IDE 1 might have activated other lineage  
18  
19 pathway(s). Downregulation of *HNF6* and the absence of DE markers after IDE 1 treatment  
20  
21 additionally support our hypothesis of non-specific lineage commitment. Further investigation is  
22  
23 required to identify the exact lineage(s). Parallel downregulation of pluripotency marker and  
24  
25 simultaneous upregulation of DE markers enable us to conclude the effectiveness of M1, M2, M4,  
26  
27 and M5 for DE formation. Effective DE differentiation includes morphological modification of  
28  
29 cells, increased expression of DE gene markers, and decreased pluripotency gene expression. Two  
30  
31 conditions, M1 and M2, demonstrate similar effects on both hESC and hiPSC differentiation to DE.  
32  
33  
34  
35

36 DE gives rise to multiple organs during embryo development. For our research interest, it is  
37  
38 important to obtain hPSC-derived DE cells that are suitable for further hepatic specialization.  
39  
40 *HNF4A* is a liver-enriched transcription factor that controls the expression of many hepatic genes  
41  
42 (Bolotin et al., 2010). Its upregulation in AA-containing conditions confirms the potential of the  
43  
44 cells to differentiate to hepatic lineage. We determined the expression of *HNF6*, which is involved  
45  
46 in hepatogenesis (Si-Tayeb et al., 2010). The upregulation of *HNF6* expression in iPS(IMR90)-4-  
47  
48 derived cells in M1, M4, and M5 may indicate hepatic commitment but needs to be investigated  
49  
50 further.  
51  
52

53  
54 To analyze whether current protocol may lead to ectoderm formation we measured the  
55  
56 expression of *SOX1* in stem cells and derivatives. *SOX1* is an ectoderm marker, whose protein  
57  
58  
59  
60

1  
2  
3 expression emerges from 4-6 days of embryoid body formation (Pekkanen-Mattila et al., 2010). A  
4 slight increase in *SOX1* expression was seen in both cell lines treated with NaB-containing media  
5 and also in iPS(IMR90)-4 cells treated with AA or IDE 1.  
6  
7  
8

9  
10 Effective formation of DE cells includes morphological change of cells, increased expression of  
11 DE markers, and decreased expression of pluripotency genes. Six-day induction protocols are more  
12 effective in generation of DE cells than four-day protocols. Two conditions, M1 and M2, exhibited  
13 similar effects on both hESC and hiPSC differentiation. The AA alone condition might serve to  
14 exclude unwanted WNT-induced neural crest formation (Leung et al., 2016) and at the same time  
15 appears to be more cost effective. High cell viability and proliferation activity under conditions M1  
16 and M2 for both cell lines allow for the generation of enough DE cells for further differentiation.  
17  
18 Two compositions of AA and NaB from two different companies appeared to be similarly effective.  
19 Due to high cell mortality, which we observed in our experiments, we do not consider NaB as a  
20 suitable component for obtaining sufficient number of DE cells for downstream analyses and  
21 applications.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **4 MATERIALS AND METHODS**

### 37 **4.1 Cell lines**

38  
39 The hESC line WA07 (RRID:CVCL\_9772) and hiPSC line iPS(IMR90)-4 (RRID:CVCL\_C437)  
40 were purchased from WiCell research institute Inc (Madison, USA) and cultured on Matrigel (BD  
41 Biosciences) with daily changes of mTeSR™1 medium (STEMCELL™ Technologies). Subculture  
42 was performed every 4-5 days using Versene 1:5000 (Invitrogen, 15040033) for cell detachment.  
43  
44  
45  
46  
47  
48

### 49 **4.2 Stem cells differentiation to DE**

50  
51 Two days after passaging, DE induction was performed for six days. RPMI-1640 medium (Gibco,  
52 31870-025), supplemented with 1x GlutaMAX™ (Gibco, 35050-038) and 1x B-27 (Gibco, 17504-  
53 044) was a base differentiation medium (DM). Six different mixtures of growth factors and/or small  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 molecules in DM were used (Table 1). Condition 1 (M1) contained 100 ng/ml AA (PeproTech, 120-  
4 14E) in DM. Condition 2 (M2) contained 100 ng/ml AA and 75 ng/ml Wnt-3a (R&D Systems,  
5 5036-WN-010) in DM. Condition 3 (M3) was a mixture of 100 ng/ml AA and 1 mM sodium  
6 butyrate (NaB, Millipore, 19-137) in the first day, followed with 100 ng/ml AA and 0.5 mM NaB  
7 for the following five days. Condition 4 (M4) contained 100 ng/ml AA and 1 mM sodium butyrate  
8 (NaB, Abcam, UK) in the first day, followed with 100 ng/ml AA and 0.5 mM NaB for the  
9 following five days. Condition 5 (M5) contained 100 ng/ml AA and 1 mM sodium butyrate (NaB,  
10 Sigma Aldrich, B5887) in the first day, followed with 100 ng/ml AA and 0.5 mM NaB for the  
11 following five days. Condition 6 (M6) represents 100 nM IDE 1 (Tocris, 4015) in DM.  
12 Differentiation media were renewed daily. Differentiation experiments were performed three times  
13 and analyzed on differentiation days 0, 1, 4, and 6.

#### 27 **4.3 RNA isolation and cDNA conversion**

28  
29 At each check point day, cells were lysed using an RLT-buffer (Qiagen). Total RNAs were  
30 extracted using an RNeasy Mini kit (Qiagen, 74104) according to the instructions of the  
31 manufacturer. The RNA to cDNA conversion was performed using a High Capacity RNA-to-cDNA  
32 kit (Applied Biosystems, 4387406).

#### 38 **4.4 Quantitative PCR (qPCR) and hierarchical clustering analyses**

39  
40 qPCR reactions of the obtained cDNA samples were carried out on a StepOnePlus Real-Time PCR  
41 System (Applied Biosystems) using a Fast SYBR Green Master Mix (Applied Biosystems,  
42 4385612) or TaqMan Universal Master Mix II (Applied Biosystems, 4440038). Ribosomal protein,  
43 large, P0 (*RPLP0*) was used as a housekeeping gene. All the used primers and TaqMan Gene  
44 Expression Assay mixes are listed in Table 2. All primers were designed by Primer Express v2.0  
45 software (Applied Biosystems) (Kanninen et al., 2016a), except the primers for *OCT4* (Yu et al.,  
46 2007) and *HNF3B* (D'Amour et al., 2005), and they were synthesized by Oligomer Oy (Helsinki,  
47 Finland). The relative quantification of each target gene in comparison with the housekeeping gene  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 was made by a standard curve method based on a published mathematical model (Pfaffl, 2001). The  
4  
5 relative gene expression was calculated with reference to the undifferentiated hPSCs on day 0.  
6

7 In order to investigate the gene expression dynamics under different differentiations conditions,  
8  
9 we performed a hierarchical clustering of the conditions using a complete agglomeration method  
10  
11 with Euclidean distance measure using the heatmap.2 function in R package “gplots”.  
12  
13

#### 14 **4.5 Immunofluorescent staining**

15  
16 Cell culturing for immunostaining was performed in either 8-well Lab-Tek® Chamber Slide™  
17  
18 systems (Nunc, 177445) or black 96-well  $\mu$ -plates (ibidi, 89626). The duration of differentiation  
19  
20 experiments was six days. The cells were fixed with 4% paraformaldehyde for 10 minutes and then  
21  
22 permeabilized with either 0.1% Triton X-100 or 0.5% Saponin for 10 minutes, followed with  
23  
24 blocking by 10% normal goat or donkey serum (Millipore) for one hour. Then the cells were stained  
25  
26 with the primary antibodies (Table 3). Negative controls included omission of the primary  
27  
28 antibodies and staining with nonimmunized normal rabbit IgG (Peprotech 500-P00), goat IgG  
29  
30 (Santa Cruz Biotechnology sc-2018), and mouse IgG (Peprotech 500-M00) (Supplementary Figure  
31  
32 S1). On the following day the cells were stained with the secondary antibody conjugated with Alexa  
33  
34 Fluor 594 (Invitrogen, 1:400) for one hour. After that, cell nuclei were stained with DAPI (Sigma-  
35  
36 Aldrich, D8417, 12.5  $\mu$ g/ml in MilliQ water) for two minutes. The cells in Chamber Slides were  
37  
38 mounted with a ProLong® Gold antifade reagent (Invitrogen, P36934). Samples in 96-well  $\mu$ -plates  
39  
40 were filled up with 1xPBS. The protein expression was visualized with two microscopes: a confocal  
41  
42 microscope Leica TCS SP5II HCS A with aHCX PL APO 20x/0.7 Imm Cor (glycerol) objective  
43  
44 and fluorescence wide field microscope Leica DM6000B with a 20x/0.7 HC PL APO CS wd=0.59  
45  
46 objective.  
47  
48  
49  
50

#### 51 **4.6 Statistical analyses**

52  
53 Statistical significance was determined by one-way analysis of variance followed by Bonferroni  
54  
55 posttest (SigmaPlot 11.0, RRID:SCR\_003210). Differences of  $P < 0.05$  (\*),  $P < 0.01$  (\*\*), and  $P <$   
56  
57  
58  
59  
60

1  
2  
3 0.001 (\*\*\*) in relative gene expression between differentiated cells and undifferentiated hPSCs on  
4 day 0 were considered significant (Figures 3-4). For each differentiation condition, differences of  $P$   
5  $< 0.05$  (\*) and  $P < 0.001$  (\*\*\*) in relative gene expression of DE and hepatic markers between day  
6  
7 4 and day 6 were considered significant (Figures 3-4).  
8  
9

#### 10 11 12 13 14 **ACKNOWLEDGMENTS**

15  
16 This work was supported by grants from Academy of Finland (Nos. 294193 and 294194 to Y.-R.L.)  
17 and Finnish National Agency for Education (TM-15-9578 to Y.-R.L. for M.S.B.). M.S.B.  
18 acknowledges support from the Doctoral Programme in Drug Research in University of Helsinki.  
19  
20 L.K.K. acknowledges support from the Doctoral Programme in Materials Research and  
21 Nanosciences in University of Helsinki. We would like to thank the Light Microscopy Unit at the  
22 Institute of Biotechnology for providing confocal microscopy, Dr. Tomi Mäkelä at the Research  
23 Programs Unit, Faculty of Medicine for providing StepOnePlus system, and Dr. Petri Auvinen at  
24 the Institute of Biotechnology for providing NanoDrop spectrophotometer.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

#### 36 **CONFLICT OF INTEREST**

37  
38 The authors declare no conflict of interest.  
39  
40  
41  
42

#### 43 **AUTHOR CONTRIBUTIONS**

44  
45 Y.-R.L. designed the research; M.S.B., L.K.K., and Y.-R.L. performed the experiments; M.S.B.,  
46 S.K., A.W.L., and Y.-R.L. analyzed the data; M.S.B., A.W.L., and Y.-R.L. wrote the paper. All  
47 authors read the manuscript.  
48  
49  
50  
51  
52

#### 53 **FIGURE LEGENDS**

54  
55  
56  
57  
58  
59  
60

1  
2  
3 **FIGURE 1** Morphology of WA07 cells and their derivatives on day 1, day 4, and day 6 of  
4 differentiation. Scale bars = 100  $\mu\text{m}$ . ND: no data.

5  
6  
7 **FIGURE 2** Morphology of iPS(IMR90)-4 cells and their derivatives on day 1, day 4, and day 6 of  
8 differentiation. Scale bars = 100  $\mu\text{m}$ .

9  
10  
11 **FIGURE 3** Relative mRNA expression of the pluripotency (a, b), DE (c-f), hepatic (g), bile duct  
12 (h), mesendoderm (i), and ectoderm (j) markers in the WA07 cells during the differentiation. The  
13 mRNA expression was analyzed by real-time qPCR. Relative mRNA expression was normalized to  
14 the housekeeping gene *RPLP0*, and fold inductions were calculated with reference to the  
15 undifferentiated WA07 cells on day 0. N = 3 biological samples. Error bars are SD. \*  $P < 0.05$ , \*\*\*  
16  $P < 0.01$ , and \*\*\*  $P < 0.001$  in comparison with day 0 are shown above bars. \*  $P < 0.05$  and \*\*\*  $P$   
17  $< 0.001$  between day 4 and day 6 are shown above lines. M1-M6 are medium conditions according  
18 to Table 1. ND: no data.

19  
20  
21 **FIGURE 4** Relative mRNA expression of the pluripotency (a, b), DE (c-f), hepatic (g), bile duct  
22 (h), mesendoderm (i), and ectoderm (j) markers in the iPS(IMR90)-4 cells during the  
23 differentiation. The mRNA expression was analyzed by real-time qPCR. Relative mRNA  
24 expression was normalized to the housekeeping gene *RPLP0*, and fold inductions were calculated  
25 with reference to the undifferentiated iPS(IMR90)-4 cells on day 0. N = 3 biological samples. Error  
26 bars are SD. \*  $P < 0.05$ , \*\*\*  $P < 0.01$ , and \*\*\*  $P < 0.001$  in comparison with day 0 are shown  
27 above bars. \*\*\*  $P < 0.001$  between day 4 and day 6 are shown above lines. M1-M6 are medium  
28 conditions according to Table 1.

29  
30  
31 **FIGURE 5** Heat map representing gene expression levels and hierarchical clustering of different  
32 treatments. The values are log<sub>2</sub> transformed relative gene expressions. The dendrogram represents  
33 the distance (dissimilarity) between treatment clusters. The intensity of the red and blue color  
34 indicates high and low expression levels, respectively. Data analysis was performed with gplots  
35 package in R (version 3.3.1).



1  
2  
3 **FIGURE 6** Immunostaining of the pluripotency, DE, and hepatic markers in the WA07 cells  
4 differentiated in conditions M1 and M2 for six days. Scale bars = 100  $\mu$ m.  
5  
6

7 **FIGURE 7** Immunostaining of the pluripotency, DE, and hepatic markers in the iPS(IMR90)-4  
8 cells differentiated in conditions M1 and M2 for six days. Scale bars = 100  $\mu$ m.  
9  
10

11 **TABLE 1** Medium composition for the DE induction  
12

13 **TABLE 2** Primers and TaqMan® Gene Expression Assay mixes used in qPCR  
14

15 **TABLE 3** Antibodies used in immunofluorescent staining  
16  
17

## 18 **SUPPORTING INFORMATION**

19  
20 Supplementary Figure S1 is found online in the supporting information tab for this article.  
21  
22

## 23 **REFERENCES**


- 24  
25 Ang SL, Wierda A, Wong D, Stevens KA, Cascio S, Rossant J, Zaret KS. 1993. The formation and  
26 maintenance of the definitive endoderm lineage in the mouse: involvement of  
27 HNF3/forkhead proteins. *Development* 119(4):1301-1315.  
28  
29  
30 Boffa LC, Vidali G, Mann RS, Allfrey VG. 1978. Suppression of histone deacetylation in vivo and  
31 in vitro by sodium butyrate. *The Journal of biological chemistry* 253(10):3364-3366.  
32  
33  
34 Bolotin E, Liao H, Ta TC, Yang C, Hwang-Verslues W, Evans JR, Jiang T, Sladek FM. 2010.  
35 Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target  
36 genes using protein binding microarrays. *Hepatology* 51(2):642-653.  
37  
38  
39  
40  
41  
42 Borowiak M, Maehr R, Chen S, Chen AE, Tang W, Fox JL, Schreiber SL, Melton DA. 2009. Small  
43 molecules efficiently direct endodermal differentiation of mouse and human embryonic stem  
44 cells. *Cell stem cell* 4(4):348-358.  
45  
46  
47  
48  
49 Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. 2003. Functional  
50 expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell*  
51 113(5):643-655.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 D'Amour KA, Agulnick AD, Eliazar S, Kelly OG, Kroon E, Baetge EE. 2005. Efficient  
4  
5 differentiation of human embryonic stem cells to definitive endoderm. *Nature biotechnology*  
6  
7 23(12):1534-1541.  
8  
9  
10 Gadue P, Huber TL, Paddison PJ, Keller GM. 2006. Wnt and TGF-beta signaling are required for  
11  
12 the induction of an in vitro model of primitive streak formation using embryonic stem cells.  
13  
14 *Proceedings of the National Academy of Sciences of the United States of America*  
15  
16 103(45):16806-16811.  
17  
18  
19 Goicoa S, Alvarez S, Ricordi C, Inverardi L, Dominguez-Bendala J. 2006. Sodium butyrate  
20  
21 activates genes of early pancreatic development in embryonic stem cells. *Cloning and stem*  
22  
23 *cells* 8(3):140-149.  
24  
25  
26 Hay DC, Fletcher J, Payne C, Terrace JD, Gallagher RC, Snoeys J, Black JR, Wojtacha D, Samuel  
27  
28 K, Hannoun Z, Pryde A, Filippi C, Currie IS, Forbes SJ, Ross JA, Newsome PN, Iredale JP.  
29  
30 2008a. Highly efficient differentiation of hESCs to functional hepatic endoderm requires  
31  
32 ActivinA and Wnt3a signaling. *Proceedings of the National Academy of Sciences of the*  
33  
34 *United States of America* 105(34):12301-12306.  
35  
36  
37 Hay DC, Zhao D, Fletcher J, Hewitt ZA, McLean D, Urruticoechea-Uriguen A, Black JR, Elcombe  
38  
39 C, Ross JA, Wolf R, Cui W. 2008b. Efficient differentiation of hepatocytes from human  
40  
41 embryonic stem cells exhibiting markers recapitulating liver development in vivo. *Stem*  
42  
43 *cells* 26(4):894-902.  
44  
45  
46 Jiang J, Au M, Lu K, Eshpeter A, Korbitt G, Fisk G, Majumdar AS. 2007. Generation of insulin-  
47  
48 producing islet-like clusters from human embryonic stem cells. *Stem cells* 25(8):1940-1953.  
49  
50  
51 Kanai-Azuma M, Kanai Y, Gad JM, Tajima Y, Taya C, Kurohmaru M, Sanai Y, Yonekawa H,  
52  
53 Yazaki K, Tam PP, Hayashi Y. 2002. Depletion of definitive gut endoderm in Sox17-null  
54  
55 mutant mice. *Development* 129(10):2367-2379.  
56  
57  
58  
59  
60

- 1  
2  
3 Kanninen LK, Harjumaki R, Peltoniemi P, Bogacheva MS, Salmi T, Porola P, Niklander J, Smutny  
4  
5 T, Urtti A, Yliperttula ML, Lou YR. 2016a. Laminin-511 and laminin-521-based matrices  
6  
7 for efficient hepatic specification of human pluripotent stem cells. *Biomaterials* 103:86-100.  
8  
9  
10 Kanninen LK, Porola P, Niklander J, Malinen MM, Corlu A, Guguen-Guillouzo C, Urtti A,  
11  
12 Yliperttula ML, Lou YR. 2016b. Hepatic differentiation of human pluripotent stem cells on  
13  
14 human liver progenitor HepaRG-derived acellular matrix. *Experimental cell research*  
15  
16 341(2):207-217.  
17  
18  
19 Katoh M, Katoh M. 2006. CER1 is a common target of WNT and NODAL signaling pathways in  
20  
21 human embryonic stem cells. *International journal of molecular medicine* 17(5):795-799.  
22  
23  
24 Kruh J. 1982. Effects of sodium butyrate, a new pharmacological agent, on cells in culture.  
25  
26 *Molecular and cellular biochemistry* 42(2):65-82.  
27  
28  
29 Kubo A, Shinozaki K, Shannon JM, Kouskoff V, Kennedy M, Woo S, Fehling HJ, Keller G. 2004.  
30  
31 Development of definitive endoderm from embryonic stem cells in culture. *Development*  
32  
33 131(7):1651-1662.  
34  
35  
36 Leung AW, Murdoch B, Salem AF, Prasad MS, Gomez GA, Garcia-Castro MI. 2016. WNT/beta-  
37  
38 catenin signaling mediates human neural crest induction via a pre-neural border  
39  
40 intermediate. *Development* 143(3):398-410.  
41  
42  
43 Lindsley RC, Gill JG, Kyba M, Murphy TL, Murphy KM. 2006. Canonical Wnt signaling is  
44  
45 required for development of embryonic stem cell-derived mesoderm. *Development*  
46  
47 133(19):3787-3796.  
48  
49  
50 McGrath KE, Koniski AD, Maltby KM, McGann JK, Palis J. 1999. Embryonic expression and  
51  
52 function of the chemokine SDF-1 and its receptor, CXCR4. *Developmental biology*  
53  
54 213(2):442-456.  
55  
56  
57  
58  
59  
60



- 1  
2  
3 Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M,  
4  
5 Yamanaka S. 2003. The homeoprotein Nanog is required for maintenance of pluripotency in  
6  
7 mouse epiblast and ES cells. *Cell* 113(5):631-642.  
8
- 9  
10 Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, Smith  
11  
12 A. 1998. Formation of pluripotent stem cells in the mammalian embryo depends on the POU  
13  
14 transcription factor Oct4. *Cell* 95(3):379-391.  
15
- 16  
17 Pekkanen-Mattila M, Peltto-Huikko M, Kujala V, Suuronen R, Skottman H, Aalto-Setälä K, Kerkela  
18  
19 E. 2010. Spatial and temporal expression pattern of germ layer markers during human  
20  
21 embryonic stem cell differentiation in embryoid bodies. *Histochemistry and cell biology*  
22  
23 133(5):595-606.  
24
- 25  
26 Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR.  
27  
28 *Nucleic acids research* 29(9):e45.  
29
- 30  
31 Ramirez JM, Gerbal-Chaloin S, Milhavet O, Qiang B, Becker F, Assou S, Lemaitre JM, Hamamah  
32  
33 S, De Vos J. 2011. Brief report: benchmarking human pluripotent stem cell markers during  
34  
35 differentiation into the three germ layers unveils a striking heterogeneity: all markers are not  
36  
37 equal. *Stem cells* 29(9):1469-1474.  
38
- 39  
40 Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. 2014. Pluripotent stem cell-derived hepatocyte-  
41  
42 like cells. *Biotechnology advances* 32(2):504-513.  
43
- 44  
45 Shen MM. 2007. Nodal signaling: developmental roles and regulation. *Development* 134(6):1023-  
46  
47 1034.  
48
- 49  
50 Si-Tayeb K, Lemaigre FP, Duncan SA. 2010. Organogenesis and development of the liver.  
51  
52 *Developmental cell* 18(2):175-189.  
53
- 54  
55 Spence JR, Lange AW, Lin SC, Kaestner KH, Lowy AM, Kim I, Whitsett JA, Wells JM. 2009.  
56  
57 Sox17 regulates organ lineage segregation of ventral foregut progenitor cells.  
58  
59 *Developmental cell* 17(1):62-74.  
60

- 1  
2  
3 Tahamtani Y, Azarnia M, Farrokhi A, Sharifi-Zarchi A, Aghdami N, Baharvand H. 2013.  
4  
5 Treatment of human embryonic stem cells with different combinations of priming and  
6  
7 inducing factors toward definitive endoderm. *Stem cells and development* 22(9):1419-1432.  
8  
9  
10 Toivonen S, Lundin K, Balboa D, Ustinov J, Tamminen K, Palgi J, Trokovic R, Tuuri T, Otonkoski  
11  
12 T. 2013. Activin A and Wnt-dependent specification of human definitive endoderm cells.  
13  
14 *Experimental cell research* 319(17):2535-2544.  
15  
16 Wilkinson DG, Bhatt S, Herrmann BG. 1990. Expression pattern of the mouse T gene and its role in  
17  
18 mesoderm formation. *Nature* 343(6259):657-659.  
19  
20  
21 Xu RH, Sampsell-Barron TL, Gu F, Root S, Peck RM, Pan G, Yu J, Antosiewicz-Bourget J, Tian S,  
22  
23 Stewart R, Thomson JA. 2008. NANOG is a direct target of TGFbeta/activin-mediated  
24  
25 SMAD signaling in human ESCs. *Cell stem cell* 3(2):196-206.  
26  
27  
28 Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir  
29  
30 GA, Ruotti V, Stewart R, Slukvin, II, Thomson JA. 2007. Induced pluripotent stem cell lines  
31  
32 derived from human somatic cells. *Science* 318(5858):1917-1920.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Human pluripotent stem cells

Human pluripotent stem cell – derived definitive endoderm cells



Graphical abstract

199x197mm (300 x 300 DPI)

**TABLE 1** Medium composition for the DE induction

<b>Condition</b>	<b>DE priming (day 0) medium composition</b>	<b>DE induction (days 1-5) medium composition</b>
M1	DM, 100 ng/ml AA	DM, 100 ng/ml AA
M2	DM, 100 ng/ml AA, 75 ng/ml Wnt-3a	DM, 100 ng/ml AA, 75 ng/ml Wnt-3a
M3	DM, 100 ng/ml AA, 1 mM NaB (Millipore)	DM, 100 ng/ml AA, 0.5 mM NaB (Millipore)
M4	DM, 100 ng/ml AA, 1 mM NaB (Abcam)	DM, 100 ng/ml AA, 0.5 mM NaB (Abcam)
M5	DM, 100 ng/ml AA, 1 mM NaB (Sigma)	DM, 100 ng/ml AA, 0.5 mM NaB (Sigma)
M6	DM, 100 nM IDE 1	DM, 100 nM IDE 1

DM: RPMI-1640, 1 x GlutaMAX™, and 1 x B-27

**TABLE 2** Primers and TaqMan® Gene Expression Assay mixes used in qPCR

<b>Gene</b>	<b>Accession</b>	<b>Size (bp)</b>	<b>Sequence (5' to 3')</b>
<i>RPLP0</i>	NM_001002.3	74	F: AATCTCCAGGGGCACCATT
	NM_053275.3		R: CGCTGGCTCCCACCTTGT
<i>OCT4</i>	NM_002701.4	161	F: CAGTGCCCGAAACCCACAC
	NM_203289.4		R: GGAGACCCAGCAGCCTCAAA
	NM_001173531.1		
<i>NANOG</i>	NM_024865.2	80	F: GCAGAAGGCCTCAGCACCTA
			R: GGTTCACAGTCGGGTTTTCAC
<i>HNF3B</i>	NM_021784.4	89	F: GGGAGCGGTGAAGATGGA
	NM_153675.2		R: TCATGTTGCTCACGGAGGAGTA
<i>BRACHYURY</i>	NM_001270484.1	118	F: AGAACGGCAGGAGGATGTTTCC
	NM_003181.3		R: ACGTACTTCCAGCGGTGGTTGT
<b>Gene</b>	<b>TaqMan® Gene Expression Assay ID</b>		
<i>RPLP0</i>	Hs99999902_m1		
<i>CER1</i>	Hs00193796_m1		
<i>SOX17</i>	Hs00751752_s1		
<i>CXCR4</i>	Hs00607978_s1		
<i>HNF4A</i>	Hs00230853_m1		
<i>HNF6</i>	Hs00413554_m1		
<i>SOX1</i>	Hs01057642_s1		



**TABLE 3** Antibodies used in immunofluorescent staining

<b>Antibody</b>	<b>Manufacturer</b>	<b>RRID</b>	<b>Dilution ratio</b>
rabbit anti-OCT4	Santa Cruz Biotechnology sc-9081	AB_2167703	1:500
rabbit-anti NANOG	Abcam ab21624	AB_446437	1:50
rabbit anti-HNF4A	Sigma-Aldrich HPA004712	AB_1079075	1:91
goat anti-NANOG	R&D Systems AF1997	AB_355097	1:40
goat anti-SOX17	R&D Systems AF1924	AB_355060	1:50
goat anti-HNF3B	Santa Cruz Biotechnology sc-6554	AB_2262810	1:50
mouse anti-AFP	Sigma-Aldrich A8452	AB_258392	1:500





FIGURE 1 Morphology of WA07 cells and their derivatives on day 1, day 4, and day 6 of differentiation. Scale bars = 100 μm. ND: no data.

278x139mm (300 x 300 DPI)

Peer Review



27  
28  
29

FIGURE 2 Morphology of iPS(IMR90)-4 cells and their derivatives on day 1, day 4, and day 6 of differentiation. Scale bars = 100  $\mu$ m.

30  
31  
32

236x139mm (300 x 300 DPI)




FIGURE 3 Relative mRNA expression of the pluripotency (a, b), DE (c-f), hepatic (g), bile duct (h), mesendoderm (i), and ectoderm (j) markers in the WA07 cells during the differentiation. The mRNA expression was analyzed by real-time qPCR. Relative mRNA expression was normalized to the housekeeping gene *RPLP0*, and fold inductions were calculated with reference to the undifferentiated WA07 cells on day 0.

N = 3 biological samples. Error bars are SD. \*  $P < 0.05$ , \*\*  $P < 0.01$ , and \*\*\*  $P < 0.001$  in comparison with day 0 are shown above bars. \*  $P < 0.05$  and \*\*\*  $P < 0.001$  between day 4 and day 6 are shown above lines. M1-M6 are medium conditions according to Table 1. ND: no data.

240x310mm (300 x 300 DPI)




FIGURE 4 Relative mRNA expression of the pluripotency (a, b), DE (c-f), hepatic (g), bile duct (h), mesendoderm (i), and ectoderm (j) markers in the iPS(IMR90)-4 cells during the differentiation. The mRNA expression was analyzed by real-time qPCR. Relative mRNA expression was normalized to the housekeeping gene *RPLP0*, and fold inductions were calculated with reference to the undifferentiated iPS(IMR90)-4 cells on day 0. N = 3 biological samples. Error bars are SD. \*  $P < 0.05$ , \*\*  $P < 0.01$ , and \*\*\*  $P < 0.001$  in comparison with day 0 are shown above bars. \*\*\*  $P < 0.001$  between day 4 and day 6 are shown above lines. M1-M6 are medium conditions according to Table 1.

239x303mm (300 x 300 DPI)




FIGURE 5 Heat map representing gene expression levels and hierarchical clustering of different treatments. The values are log<sub>2</sub> transformed relative gene expressions. The dendrogram represents the distance (dissimilarity) between treatment clusters. The intensity of the red and blue color indicates high and low expression levels, respectively. Data analysis was performed with gplots package in R (version 3.3.1).

199x321mm (300 x 300 DPI)




FIGURE 6 Immunostaining of the pluripotency, DE, and hepatic markers in the WA07 cells differentiated in conditions M1 and M2 for six days. Scale bars = 100  $\mu$ m.

168x206mm (300 x 300 DPI)




FIGURE 7 Immunostaining of the pluripotency, DE, and hepatic markers in the iPS(IMR90)-4 cells differentiated in conditions M1 and M2 for six days. Scale bars = 100  $\mu$ m.

169x205mm (300 x 300 DPI)